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Patient blood management in orthopaedic surgery:
a four-year follow-up of transfusion requirements and blood loss from 
2008 to 2011 at the Balgrist University Hospital in Zurich, Switzerland
Oliver M. Theusinger1, Stephanie L. Kind1, Burkhardt Seifert2, Alain Borgeat3, Christian Gerber3, Donat R. Spahn1
1Institute of Anaesthesiology, University and University Hospital Zurich; 2Division of Biostatistics, Institute of 
Social and Preventive Medicine, University of Zurich; 3Department of Orthopaedics, University of Zurich, Balgrist 
Hospital, Zurich, Switzerland
Introduction
Despite risks, red blood cell (RBC) transfusions 
remain common practice in elective orthopaedic 
surgery1,2. In addition to transfusion risks, such as, 
transmission of bacterial or viral infections, febrile 
transfusion reactions, transfusion-related acute lung 
injury, a relationship of causality has recently been 
shown between allogeneic RBC transfusions and 
increased mortality, morbidity and immunomodulation3. 
When considering the burden of cost on public health 
systems, RBC transfusions become a relevant issue4. The 
approximate cost of administering one unit of RBC is 
US$ 700-1,200 and treating the associated side effects 
may cost $1,0005,6.
In orthopaedic surgery, the prevalence of pre-operative 
anaemia varies from 20% to 51%7-9 and is defined by the 
World Health Organisation (WHO) as a haemoglobin level 
≤12 g/dL in women and ≤13 g/dL in men, corresponding 
to a haematocrit of ≤36% in woman and ≤39% in men. 
Pre-operative anaemia is an independent risk factor 
for increased 30-day mortality and major morbidity in 
all surgical patients10-12. In up to 30% of patients, iron 
deficiency is the cause of anaemia and should be corrected 
at least 4 weeks prior to surgery to achieve optimal results1,9. 
Optimising haemoglobin mass before orthopaedic surgery 
as well as limiting intra-operative blood loss is associated 
with improved outcomes after 90 days13.
The WHO urges member states to utilise transfusion 
alternatives and develop individualised Patient Blood 
Management (PBM) programmes reducing transfusion 
needs. The three pillars of PBM are: (i) detection and 
treatment of pre-operative anaemia, (ii) reduction 
in peri-operative RBC loss, and (iii) harnessing and 
optimising the patient-specific physiological reserve of 
Background. The aim of this study was to investigate the impact of the introduction of a Patient 
Blood Management (PBM) programme in elective orthopaedic surgery on immediate pre-operative 
anaemia, red blood cell (RBC) mass loss, and transfusion.
Materials and methods. Orthopaedic operations (hip, n=3,062; knee, n=2,953; and spine, n=2,856) 
performed between 2008 and 2011 were analysed. Period 1 (2008), was before the introduction of the 
PBM programme and period 2 (2009 to 2011) the time after its introduction. Immediate pre-operative 
anaemia, RBC mass loss, and transfusion rates in the two periods were compared.
Results. In hip surgery, the percentage of patients with immediate pre-operative anaemia decreased 
from 17.6% to 12.9% (p<0.001) and RBC mass loss was unchanged, being 626±434 vs 635±450 mL 
(p=0.974). Transfusion rate was significantly reduced from 21.8% to 15.7% (p<0.001). The number 
of RBC units transfused remained unchanged (p=0.761). In knee surgery the prevalence of immediate 
pre-operative anaemia decreased from 15.5% to 7.8% (p<0.001) and RBC mass loss reduced from 
573±355 to 476±365 mL (p<0.001). The transfusion rate dropped from 19.3% to 4.9% (p<0.001). RBC 
transfusions decreased from 0.53±1.27 to 0.16±0.90 units (p<0.001). In spine surgery the prevalence 
of immediate pre-operative anaemia remained unchanged (p=0.113), RBC mass loss dropped from 
551±421 to 404±337 mL (p<0.001), the transfusion rate was reduced from 18.6 to 8.6% (p<0.001) 
and RBC transfusions decreased from 0.66±1.80 to 0.22±0.89 units (p=0.008). 
Discussion. Detection and treatment of pre-operative anaemia, meticulous surgical technique, 
optimal surgical blood-saving techniques, and standardised transfusion triggers in the context of PBM 
programme resulted in a lower incidence of immediate pre-operative anaemia, reduction in RBC mass 
loss, and a lower transfusion rate.
Keywords: anaesthesia audit, pre-anaesthetic assessment, blood transfusion, orthopaedic surgery.
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anaemia (including restrictive haemoglobin transfusion 
triggers)14-17. 
The aim of this study was to investigate the effects of 
implementing a PBM programme on: (i) immediate pre-
operative anaemia, (ii) intra-operative RBC mass loss 
as well as blood volume loss, and (iii) transfusion rates.
Material and methods 
Data collection was started after obtaining 
approval from the local ethics committee (Kantonale 
Ethikkommission Zurich, Switzerland, study number 
KEK-ZH-Nr. 2010-0263/4).
The PBM programme was initiated in 2009 at the 
Department of Orthopaedics, University of Zurich, 
Balgrist Hospital, Zurich, Switzerland. Data from 2008 
were analysed retrospectively and were considered the 
baseline with regards to the prevalence of immediate 
pre-operative anaemia, intra-operative RBC mass loss 
and blood volume loss, and overall transfusion rate of 
RBC, platelet concentrates and fresh-frozen plasma 
(period 1). The span from 2009 to 2011 was analysed 
prospectively and was considered the time after the 
introduction of PBM (period 2). 
The PBM programme at the Department of 
Orthopaedics in Balgrist Hospital had the following 
components: (i) investigation for pre-operative 
anaemia and treatment, (ii) reduction of intra-operative 
blood loss by surgical, anaesthesiological and 
pharmacological techniques, and (iii) lowering of the 
transfusion trigger to a haemoglobin level of ≤8 g/dL; 
a reduction of 2 g/dL compared to 200814,15.
In the PBM programme all patients undergoing 
elective orthopaedic surgery (hip, knee and spine 
interventions) had to be reported (name of the patient, 
type of surgery, date of surgery) approximately 4 weeks 
prior to surgery to a designated anaesthesiologist of 
the Institute of Anaesthesiology at the University 
Hospital Zurich, Zürich, Switzerland. If reported the 
patient's general practitioner was contacted to get the 
latest haemoglobin concentration as well as C-reactive 
protein level. 
Criteria for treating anaemic patients with intravenous 
iron and erythropoietin were that the patient was older 
than 18 years, scheduled to undergo major orthopaedic 
surgery (hip or knee arthroplasty or back surgery 
including scoliosis, laminectomy, decompression and 
disc hernia), had a haemoglobin <13.0 g/dL if male or 
<12.0 g/dL if female, and that it was 4±1 weeks prior 
to surgery. Criteria for not treating anaemic patients 
with intravenous iron and erythropoietin were that 
the patient had active severe infection/inflammation 
(defined as serum C-reactive protein >20 mg/L), 
diagnosed malignancy, known history of hepatitis B/C 
or positivity for human immunodeficiency virus, was 
receiving immunosuppressive or myelosuppressive 
therapy, had a concurrent medical condition(s) 
that, in the view of the investigator, would prevent 
compliance or participation or jeopardise the patient's 
health, was pregnant or breastfeeding, had a history of 
thromboembolic events, severe peripheral, coronary or 
carotid artery disease, weighed <50 kg, and was not able 
to understand the German language. Furthermore data 
were not collected for operations performed on minors 
(defined as individuals under 18 years of age) or any 
revisions within 8 weeks of the initial surgery.
In cases of anaemia a recommended therapy 
was administered consisting of 1,000 mg of iron 
carboxymaltose (Ferinject®, Vifor International AG, St. 
Gallen, Switzerland, price Swiss Fr 254.80) intravenously 
over 15 minutes, 40,000 IU of erythropoietin alpha 
subcutaneously (Eprex®, Janssen-Cilag AG, Baar, Zug, 
Switzerland, price Swiss Fr 481.80), 1 mg vitamin B12 
subcutaneously (Betolvex®, Actavis Switzerland AG, 
Regensdorf, Switzerland, price Swiss Fr 1.85) and 5 mg 
folic acid (AcidumfolicumStreuli®, StreuliPharma AG, 
Uznach, Switzerland, price Swiss Fr 0.70) orally per 
day for 4 weeks. Laboratory controls after 14 days were 
advised. In cases of persisting anaemia a second dose of 
iron carboxymaltose, erythropoietin, and vitamin B12 
was administered. To reduce intra-operative blood loss, 
cell salvage, topical haemostatic agents, and meticulous 
intra-operative haemostasis were used18. Tranexamic 
acid and post-operative cell salvage were not used during 
the study period. 
Data collection
Data from database of the Department of 
Orthopaedics, Balgrist Hospital for all hip, knee, and 
spine operations performed between 2008 and 2011 
were matched with those from the laboratory and 
transfusion databases of the Central Laboratory of 
Zurich (Zurich, Switzerland) using the patient's name, 
case number and date of birth as a unique identifier. All 
data were transferred into an Excel-chart (Microsoft® 
Office 2010, Microsoft® Corporation, Redmond, WA, 
USA). Demographic data including date of birth, sex, 
weight and height, age at the date of surgery, as well as 
surgery-specific details were collected. Pre-operative 
haemoglobin and haematocrit values, up to 21 days 
before surgery, as well as haemoglobin and haematocrit 
values for post-operative days 1 to 5, were collected. The 
total number of RBC units, platelet concentrates, and 
fresh-frozen plasma units transfused during the first 5 
days after surgery were recorded. Haemoglobin values 
of the preoperative day were available for all patients 
and the prevalence of anaemia was determined. Missing 
post-operative Haemoglobin and haematocrit values led 
to the patient being excluded from RBC mass loss and 
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blood loss analysis. Pre-operative data were available for 
3,062 cases of hip surgery, 2,953 cases of knee surgery, 
and 2,856 spine operations. Complete post-operative 
data were available for 1,842, 984 and 1,432 hip, knee 
and spine operations, respectively.
The formulae used to calculate peri-operative RBC 
mass loss and blood volume loss are shown in Table I. 
Two formulae were initially used for total blood volume 
loss: one factoring in the mean haematocrit and the other 
the formula of Brecher19,20. 
Statistical analysis
Continuous variables are presented as means with 
standard deviations or medians with ranges, categorical 
variables are presented as numbers with proportions. 
Data from 2009 to 2011 were combined (period 2) 
and compared to those from 2008 (period 1) using 
the Mann-Whitney test and the chi-square test when 
appropriate. No adjustment for multiple comparisons 
was performed in this analysis. The IBM SPSS 
Statistics version 20 statistical programme (SPSS Inc., 
Chicago, IL, USA) was used for statistical analyses. 
Two-sided p values less than 0.05 were considered 
statistically significant.
Results
Demographic data and reporting
The demographic data (Table II) show that patients 
undergoing elective hip surgery (p=0.001) and knee 
surgery (p<0.001) were significantly younger in period 
2 than in period 1 (p=0.001 for hip surgery, p<0.001 for 
knee surgery). Patients undergoing elective orthopaedic 
interventions (hip, knee, and spine surgery) were 
reported 35±11 days prior to surgery to a designated 
anaesthesiologist of the Institute of Anaesthesiology at 
the University Hospital Zurich, Switzerland.
Effect of the implementation of Patient Blood 
Management on immediate pre-operative anaemia
The prevalence of immediate pre-operative anaemia 
decreased significantly from period 1 to period 2 in hip 
and knee surgery, from 17.6 % to 12.9 % (p<0.001) 
and 15.5% to 7.8% (p<0.001), respectively. In spine 
surgery immediate pre-operative anaemia stayed the 
same (12.6% vs 10.3%; p=0.113). Overall 9% of the 
reported patients were treated for anaemia with one 
dose of intravenous iron and erythropoietin. Only 15% 
of these patients needed a second treatment. On the day 
of surgery none of these patients was anaemic anymore. 
Table I - Formulae used to calculate data19,20.
Data calculated Formula used
Total RBC mass loss Uncompensated loss+compensated loss
Compensated RBC mass loss 275 mL×0.6×RBC Units transfused 
Uncompensated RBC mass loss Initial RBC Volume–Finale RBC Volume
Initial RBC mass (Hct Pre-op/100)×BV
Finale RBC mass (Hct lowest D1 to D5/100)×BV
Body surface 0.0235×(height^0.42246)×(weight^0.51456)
Estimated blood volume Woman: Body Surface×2,430 
Man: Body Surface×2,530  
Blood volume loss mean formula Total loss/((Hct pre-OP+MIN(Hct1;Hct2;Hct3;Hct4;Hct5))/200)
Blood volume loss Brecher formula EBV×LN(Hct pre-OP/MIN(Hct1;Hct2;Hct3;Hct4;Hct5))
Blood volume loss was calculated using both the Brecher formula and the formula using a mean Hct out of the preoperative and lowest post-operative values.
Table II - Demographic data of patients undergoing elective hip, knee, or spine surgery according to periods.
Hip Knee Spine
period 1 period 2 p period 1 period 2 p period 1 period 2 p
Males, % 43.70 47.40 0.201 38.50* 46.80* 0.034* 43.00 47.00 0.369
Females, % 56.30 52.60 0.202 61.50* 53.20* 0.028* 57.00 53.00 0.429
Age 64±14* 59±17* <0.001* 67±12* 61±16* <0.001* 60±15 62±15 0.893
Body mass index 26.5±5.0 26.5±5.2 0.698 30.0±6.9 28.9±5.6 0.052 26.5±4.5 26.7±5.5 0.467
N. of patients pre-op 797 2,265 710 2,243 643 2,213
N of patients post-op 387 1,455 187 797 107 1,317
Data shown are mean±SD. Period 1 shows data from the year 2008 (before the introduction of the PBM programme), period 2 refers to the years 2009-2011 
(after the introduction of the PBM program). *: significant difference between the periods. N of patients pre-op: number of patients with complete data 
pre-operatively; N. of patients post-op: number of patients with complete data post-operatively.
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The mean increase of haemoglobin was 2.00±0.48 g/dL 
from one dose of treatment. The peri-operative evolution 
of haemoglobin in period 1 and 2 is shown in Figure 1.
Effect of the implementation of Patient Blood 
Management on loss of red blood cell mass and 
blood volume
The RBC mass loss was calculated using the 
formulae in Table I and results are presented in Figure 
2 (A-C) by type of surgery. To transform the RBC mass 
loss into blood volume loss, two formulae were used 
and compared: one accounting for the mean haematocrit 
between the pre-operative value and the lowest 
post-operative value, the other being the formula of 
Brecher (Table I)19. There was no significant difference 
between these two methods in terms of calculated blood 
volume loss. The results of the two formulae regarding 
blood volume loss are presented in Figure 2 (A-C). The 
formulae showed identical results: the mean formula is, 
therefore, used to compare the two periods.
For hip surgery, RBC mass loss as well as blood 
volume loss remained unchanged when comparing 
period 1 vs period 2 [RBC mass 626±434 mL vs 
635±450 mL (p=0.974); blood loss 1,402±728 mL vs 
1,453±761 mL (p=0.462)]. In knee surgery, RBC mass 
loss and blood volume loss decreased significantly 
Figure 1 - Evolution of haemoglobin in non-anaemic and immediate preoperative anaemic patients by type of surgery and period.
 *: p<0.05 for anaemic vs non anaemic patients.
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from 573±355 mL to 476±365 (p<0.001) and from 
1,384±731 mL to 1,164±852 mL (p<0.001) in period 
1 vs period 2, respectively. In spine surgery there were 
also significant reductions in RBC mass loss (from 
551±421 mL in period 1 to 404±337 mL in period 2; 
p<0.001) and blood volume loss (from 1,143±649 mL 
to 960±730 mL; p=0.005).
Effect of the implementation of Patient Blood 
Management on transfusion rates
Transfusion rates of anaemic patients were 
consistently higher than in non-anaemic patients 
(p<0.001) in all three types of surgery and each year 
(Table III).
In hip surgery overall transfusion rates decreased 
significantly from 21.8% to 15.7% (p<0.001). A mean 
of 0.82±1.94 units of RBC was transfused in period 1 
compared to 0.62±1.96 units in period 2 (p=0.761). A 
mean of 0.12±0.73 units of fresh-frozen plasma was 
transfused in period 1 compared to 0.08±0.63 units 
in period 2 (p=0.601). Platelet transfusions remained 
unchanged at 0.01±0.71 in period 1 and 0.00±0.09 units 
in period 2 (p=0.591).
The  overa l l  t ransfus ion  ra tes  decreased 
significantly (p<0.001) in knee surgery (from 19.3% 
to 4.9%). A mean of 0.53±1.27 units of RBC was 
transfused in period 1 compared to 0.16±0.90 in 
period 2 which represented a significant reduction 
(p<0.001). Platelet transfusions remained unchanged 
(from 0.00±0.00 to 0.00±0.03 units; p=0.574) as did 
fresh-frozen plasma transfusions (from 0.02±0.25 
to 0.01±0.22 units; p=0.388) in period 1 and period 
2, respectively.
A B
C
Figure 2 - Comparison between blood volume loss calculations according to the mean formula and the Brecher formula.
 A: elective hip surgery, B: elective knee surgery, C: elective spine surgery.
 Formulae used: Blood volume loss according to the mean formula: Total loss/[(Hct pre-OP+MIN(Hct1;Hct2;Hct3;Hct4;Hct5)]/200);
 Blood volume loss according to the Brecher Formula: EBV×LN (Hct pre-OP/MIN(Hct1;Hct2;Hct3;Hct4;Hct5).
Table III - Transfusion of patients anaemic or non-anaemic 
immediately pre-operatively.
 Year Surgery Transfusion in 
non-anaemic 
patients (%)
Transfusion in 
anaemic patients 
(%)
p
2008 Hip 14.7 60.0 <0.0001
2009 Hip 10.2 38.5 <0.0001
2010 Hip 14.9 49.7 <0.0001
2011 Hip 15.5 39.9 <0.0001
  
2008 Knee 13.3 53.6 <0.0001
2009 Knee 8.4 40.8 <0.0001
2010 Knee 6.2 28.9 <0.0001
2011 Knee 5.5 37.3 <0.0001
  
2008 Spine 13.8 53.8 <0.0001
2009 Spine 9.8 40.6 <0.0001
2010 Spine 10.9 39.7 <0.0001
2011 Spine 6.8 25.6 <0.0001
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For spine surgery the overall transfusion rates 
decreased significantly (p<0.001) from 18.7% to 8.6%. 
A mean of 0.66±1.80 units of RBC was transfused 
in period 1 compared to 0.22±0.89 units in period 2 
(p=0.008). Platelet transfusions decreased significantly 
from 0.01±0.09 in period 1 to 0.00±0.00 units in period 
2 (p<0.001) and fresh-frozen plasma transfusions 
decreased significantly from 0.11±0.46 units in period 
1 to 0.03±0.30 units (p<0.001) in period 2.
Discussion
The introduction of a multidisciplinary PBM 
programme in elective orthopaedic surgery reduced 
the prevalence of immediate pre-operative anaemia, 
reduced RBC mass loss as well as the blood volume 
loss, and reduced the need for blood transfusions. This 
4-year investigation shows that immediate pre-operative 
anaemia, RBC mass loss as well as blood volume loss, and 
transfusion rates can be reduced by creating awareness, 
using preventive measures and changing culture. The 
PBM introduced at the Department of Orthopaedics 
in Balgrist Hospital is in accordance with the WHO 
2010 recommendations21 and confirms the results of a 
systematic review on the efficacy of PBM measures22.
Contacting the patients' general practitioners at 
least 4 weeks prior to surgery in order to pick up 
and treat anaemia was key in lowering the incidence 
of immediate pre-operative anaemia. A foreseeable 
obstacle to treating anaemia pre-operatively is that 
patients' operations are scheduled within less than 
4 weeks which leaves little time to correct anaemia. 
Awareness among orthopaedic surgeons and general 
practitioners regarding pre-operative anaemia needs 
to be increased in order that there is sufficient time to 
treat the anaemia prior to surgery, although there is only 
one report indicating that even short-term treatment 
with intravenous iron and an erythropoiesis-stimulating 
agent may decrease transfusion needs in surgery23. In 
accordance with the findings of Rosencher et al. in 
2005 one to two doses of erythropoietin are sufficient 
to increase haemoglobin to non-anaemic levels24. 
In an Austrian benchmark study, Gombotz et al. 
showed that up to now 90% of cases of pre-operative 
anaemia are not treated prior to elective surgery with 
expected significant blood loss resulting in a 3- to 4-fold 
increase in transfusion rates1. In 2008, the Department 
of Orthopaedics in Balgrist Hospital started with a 
relatively low immediate pre-operative anaemia rate 
of 18%, which was higher than the 7.3% observed by 
Enko et al. in 370 orthopaedic patients24 but lower than 
the 22.4% found by Seicean et al. in 24,473 spinal 
operations25,26.
In 2003, Rosencher et al. reported a blood volume 
loss of 2,143±1,165 mL in primary hip surgery and 
2,072±1,145 mL in primary knee surgery8. Our current 
data on blood volume loss are lower in hip surgery 
(1,453±761 mL) and knee surgery (1,164±852 mL). 
Oberhofer et al. reported similar results to ours with a 
total blood volume loss of 1,330±635 mL in total hip 
surgery and of 1,427±660 mL in total knee replacement 
surgery27.
In spine surgery (including scoliosis and cancer 
surgery) blood volume loss decreased to 923±580 mL. 
This is remarkably low when compared to the data in 
the meta-analysis by Chen et al., who reported a blood 
volume loss of 2,180 mL (95% CI: 1,805-2,554 mL)28. 
The differences in blood loss may be explained by 
factoring in surgical experience and techniques which 
could contribute to our findings of smaller volumes of 
blood lost. Tranexamic acid can reduce blood volume 
loss further, as described in several publications, although 
it was not used in the Department of Orthopaedics in 
Balgrist Hospital29,30.
We observed a significant reduction in administered 
blood products in relation to the surgeons accepting 
a reduction in the transfusion trigger from 10 g/dL 
to 8 g/dL and the reduction in intra-operative blood 
volume loss. The transfusion rates varied depending 
on the type of surgery from 15.7% in hip surgery to 
4.9% in knee surgery; these percentages are lower 
than those reported by Qian et al., who analysed 
54,405 total hip replacement operations in which the 
overall RBC transfusion rate was 31%31.
The use of intravenous vs oral iron is presently being 
discussed. In 2007, Theusinger et al. showed that the 
use of intravenous iron sucrose was efficacious and 
safe9. A recent study by Munoz et al. also showed the 
safety and efficacy of intravenous iron administration32. 
One of the advantages of intravenous iron is that it is 
more effective; furthermore, compliance is higher with 
intravenous iron than with oral iron. The European 
Society of Anaesthesiology recently recommended 
intravenous and oral iron with a 1B grading each, with 
some restrictions using intravenous iron only if oral 
iron is contraindicated33. The recently published meta-
analysis by Litton et al. on intravenous vs oral iron 
needs to be interpreted cautiously with regard to the 
peri-operative period34 since only 11 of the 72 studies 
considered were performed in the context of surgery and 
in only 10 of the 72 studies was ferric carboxymaltose. 
Furthermore no increase in infections was observed 
with intravenous iron in patients after surgery, and the 
combination of intravenous iron and erythropoietin 
has been found to be the most efficient therapy for 
anaemia. Interestingly, Munoz et al. recently described 
a significant reduction of nosocomial infections in 
patients undergoing orthopaedic surgery when treated 
pre-operatively with intravenous iron32.
The approximate cost of administering one unit 
of RBC is US$ 700-1,200 and treating the associated 
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side effects may cost $ 1,0005,6. The cost of the applied 
treatment of 40,000 IU erythropoietin alpha, 1 g of 
intravenous iron, vitamin B12 and folic acid was Swiss 
Fr 739.15 (~US$ 815) which is still cheaper than one 
unit of RBC and its side effects.
This study has several limitations as 2008 was 
analysed retrospectively, whereas 2009 through to 
2011 prospectively. Peri-operative data were available 
for all patients, whereas complete postoperative data 
were available for only 60% of hip operations, 33% 
of knee operations, and 50% of spinal operations. A 
possible explanation of this difference would be that 
post-operative haemoglobin levels were not measured in 
patients who had high pre-operative haemoglobin levels 
and small volumes of blood loss intra-operatively. The 
length of stay could not be analysed since the duration of 
hospitalisation was very strongly influenced by a variety 
of contracts between the Department of Orthopaedics, 
Balgrist Hospital and a number of health insurance 
companies. In addition, these contracts varied over time 
during the study period, leading to a standardised length 
of stay for all patients who underwent certain surgical 
interventions. 
The pre-operative iron status was not assessed 
systematically. We adapted the anaemia treatment 
to the local situation. Over the years we tried to 
make the orthopaedic surgeons assess their patients' 
haemoglobin level and iron status approximately 4 
weeks pre-operatively, which turned out not to be 
successful. In order to get a PBM programme running, 
the orthopaedic surgeons agreed to inform a designated 
anaesthesiologist on each patient they scheduled for 
surgery. The anaesthesiologist then contacted the patient's 
general physician who knew the patient's haemoglobin 
although only relatively few general physicians assessed 
their patients' iron status. Since we wanted the anaemic 
patients to be treated we opted for a pragmatic treatment 
including intravenous iron, erythropoietin alpha, vitamin 
B12 and folic acid. We are aware of the fact that this 
approach may appear somewhat simplistic but in the 
local situation it was the only way in which we could 
in fact have the anaemic patients treated. Now that we 
have shown to everybody that a PBM programme is 
successful, a second approach will be taken, trying to 
diagnose the patients in more detail and allowing a more 
specific treatment for the anaemia or iron deficiency.
Complications and serious adverse events could 
not be analysed due to changes in codification with 
the introduction of the Swiss DRG system and due 
to the fact that in 2008 no data on complications 
were electronically available. In addition, due to the 
International Classification of Diseases (ICD10) 
codification, it was not possible to distinguish whether 
the problem was a new diagnosis that developed during 
the current hospitalisation or whether it was present 
pre-operatively. The still relatively high proportion 
of anaemic patients is most probably due to a lack of 
reporting (some patients were simply not reported to us 
anaesthesiologists) or reporting too late (only few days 
before surgery) or patients having exclusion criteria 
(mainly language, high C-reactive protein level, known 
malignancy). 
In conclusion,  this  study shows that  the 
implementation of a PBM programme for elective hip, 
knee, and spine surgery leads to a significant reduction 
of immediate pre-operative anaemia, intra-operative 
RBC mass loss as well as the blood volume loss, and 
transfusion needs. Further studies are needed to show 
long-term effects of such programmes as well as possible 
reductions in post-operative complications, time spent 
in hospital, and costs.
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